News archive

Hi Yang Gao, PhD student at the Division of Neurogeriatrics. On February 24 you will defend your thesis "Alzheimer Disease: Subcellular Aβ mechanisms and treatment strategies", what is the main focus of the thesis?

Being affected by several cardiometabolic diseases such as diabetes, heart disease and stroke, is linked to a greatly increased risk of dementia and Alzheimer’s disease. A new twin study by researchers from Karolinska Institutet suggests that the same genes may be behind the risk of both cardiometabolic diseases and dementia. The findings have been published in European Heart Journal.

Proteins can make any inventor green with envy. It is proteins that make the body work. But when these same super-substances make mistakes, we may get sick with things like cancer or Alzheimer's disease. The job of researchers is to sort out the proteins when they malfunction.

Alzheimer disease begins decades before any symptoms, such as memory loss, start to show. Consequently, early diagnosis increases the chances of slowing the disease down with drugs. A new study on an inherited form of the disease shows that a protein called GFAP is a possible biomarker for very early stages of the disease. The study, conducted by researchers at Karolinska Institutet and published in the journal Brain, could one day lead to an earlier detection of this serious and common disease.

Researchers from the Department of Neurobiology, Care Sciences and Society (Eriksdotter group) in collaboration with the Departments of MEB (Carrero group) and Clintec (Bruchfeld group) at KI have recently had their study published in Kidney International (IF 19). This paper is the first study linking activation of cholinergic anti-inflammatory pathways to kidney damage in humans.

Researchers from Karolinska Institutet have reported new insights on how copper ions inhibit the aggregation of the amyloid-β peptide implicated in Alzheimer’s disease. The study published in JACS Au presents molecular structures of this complex, which provide a general understanding of the impact metal ions have.

A researcher from the Department of Biosciences and Nutrition, Karolinska Institutet, has received a career supporting grant from the Alzheimer's Association.

Infections treated with specialty hospital care in early- and mid-life are associated with an increased subsequent risk of Alzheimer’s and Parkinson’s diseases, but not amyotrophic lateral sclerosis (ALS), according to a study by researchers from Karolinska Institutet, published in PLOS Medicine.

Using a novel 3D imaging technology, researchers at Karolinska Institutet, among others, have been able to comprehensively characterize a part of the brain that shows perhaps the earliest accumulation of tau protein, an important biomarker for the development of Alzheimer's disease. The results, published in the journal Acta Neuropathologica, may make it possible in the future to have a more precise neuropathological diagnosis of the Alzheimer’s disease spectrum at a very early stage.

The Alzheimer's Association® will present seven awards at the Alzheimer's Association International Conference® (AAIC®) 2022, recognizing researchers for their varied expertise, noteworthy achievements and innovative contributions to the field of Alzheimer's and dementia science. Agneta Nordberg, Division of Clinical Geriatrics, received one of them.

Using proteomics and other advanced tools of molecular biology, an international team of researchers led by a group from Karolinska Institutet have found a novel way to diagnose Alzheimer’s disease by blood analysis, with a potential to uncover the underlying cause of the disease and prevent its development.

Researchers at Karolinska Institutet and SciLifeLab describe in a study published in Science how they have improved the ability of a protein to repair oxidative DNA damage and created a new protein function. Their innovative technique can lead to improved drugs for diseases involving oxidative stress, such as cancer, Alzheimer’s disease and lung diseases, but the researchers believe it has even greater potential.

Mechanisms associated with a particular diabetes drug can also help to protect against Alzheimer’s disease, a study by researchers at Karolinska Institutet and published in Neurology reports. The results indicate that the drug’s target protein can be an interesting candidate for the treatment of Alzheimer’s disease.

On April 21, the 2nd Swedish Meeting for Alzheimer's Research was organized in Aula Medica by the Center for Alzheimer Research at NVS. In total, around 450 attendees participated, of which about 300 were researchers.

Hi Richeng Jiang, PhD student at the Division of Neurogeriatrics, NVS. On May 30 you will defend your thesis ”Interplay between autophagy and amyloid beta metabolism in Alzheimer’s disease”, what's the main focus of the thesis?

On April 21, H.M Queen Silvia visited Karolinska Institutet to participate in a conference focusing on research on Alzheimer's disease, dementia and aging.

Amit Kumar and Agneta Nordberg, at the Division of Clinical Geriatrics (Nordberg Translational Molecular Imaging Lab), are awarded a grant of USD 175,000 USD over a four-year period for the project ”Understanding the role of synaptic loss in degenerative proteinopathies”.

Researchers at Karolinska Institutet have compared how well different Alzheimer’s biomarkers predict the progression of the disease and its effect on the memory. They found that early accumulation of tau proteins in the brain as measured by PET scanner was more effective at predicting memory impairment than biomarkers in the cerebrospinal fluid or amyloid plaque in the brain. The results are published in the journal Molecular Psychiatry.

A large study at Karolinska Institutet in Sweden has found a link between ADHD and dementia across generations. The study, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, shows that parents and grandparents of individuals with ADHD were at higher risk of dementia than those with children and grandchildren without ADHD.

Hi there, Ceren Emre, PhD student at the Division of Neurogeriatrics! On September 1 you will defend your thesis ”Resolving inflammation - analysis of mechanisms in relation to Alzheimer pathology and aging”. What is the main focus of your thesis?

This year, The Swedish Brain Foundation will distribute SEK 106 million in research grants. Karolinska Institutet is awarded 42% of these and includes seven researchers at the Department of Neurobiology, Health Sciences and Society (NVS) as recipients.

Center for Alzheimer Research (CAR) has started a working group on sex and gender differences in dementia. The group is led by Assistant professors Shireen Sindi and Daniel Ferreira at the Division for Clinical Geriatrics. It's their first working group and they are excited to see how this group will evolve.

Hi there, Ying Wang, PhD student at the Division of Neurogeriatrics! On June 23 you will defend your thesis “Neuroinflammation and its resolution in Alzheimer's disease". What is the main focus of your thesis?

Joana Pereira officially starts as research group leader today, June 1, although she has been managing her own group for a while now.

Hi there, Lorena Galán-Acosta, PhD student at the Division of Neurogeriatrics! On June 17 you will defend your thesis “Recombinant BRICHOS domains delivered over the blood-brain barrier : a possible way to treat Alzheimer's disease”. What is the main focus of your thesis?

Hi there, Konstantinos Poulakis, PhD student at the Division of Clinical Geriatrics! On May 28 you will defend your thesis “Alzheimer’s disease heterogeneity assessment with MRI biomarkers and unsupervised statistical learning”. What is the main focus of your thesis?

New biomarkers for Alzheimer’s disease are a priority area for researchers seeking to learn more about the disease and find possible methods of early diagnosis. Researchers at Karolinska Institutet have now studied a new PET tracer that is an important diagnostic tool for the disease. The study on the tracer substance BU99008, which is published in Molecular Psychiatry, can play a key part in the early identification of signs of Alzheimer’s disease.

Cholinesterase inhibitors are a group of drugs recommended for the treatment of Alzheimer’s disease, but their effects on cognition have been debated and few studies have investigated their long-term effects. A new study involving researchers from Karolinska Institutet and published in the journal Neurology shows persisting cognitive benefits and reduced mortality for up to five years after diagnosis.

New professors Eric Westman and Dorota Religa, both Division of Clinical Geriatrics, head and deputy head of division respectively, gave their lectures as new professors at NVS on Wednesday January 20.

Hi Una Smailovic, PhD student at the Division of Clinical Geriatrics! On January 15 you will defend your thesis “Multimodal phenotyping of synaptic damage in Alzheimer’s disease : translational perspective with focus on quantitative EEG”. What’s the main focus of the thesis?

The two used methods for detecting amyloid pathology in Alzheimer's disease give ambiguous results, with the risk of incorrect or delayed care interventions. Now, researchers at Karolinska Institutet have found genetic explanations for the differences. The study is published in Molecular Psychiatry and may be important for more individual diagnostics and the development of future drugs.

The award recognises Professor Kivipelto’s more than 20 years of research into the prevention, diagnosis and treatment of cognitive impairment, Alzheimer’s Disease and dementia.

Researchers at Karolinska Institutet have studied the incidence and regional distribution of Alzheimer’s disease biomarkers in the brains of people with Down’s syndrome. The results can bring new possibilities for earlier diagnosis and preventive treatment of dementia. The study is published in Molecular Neurodegeneration.

Hi Hazal Haytural, PhD student at the Division of Neurogeriatrics, NVS! On November 27 you will defend your thesis “Unraveling pathogenic proteins and pathways in Alzheimer disease: A focus on proteomics”. What’s the main focus of the thesis?

Dr. Ivan Nalvarte, a Senior Researcher at the Department of Biosciences and Nutrition (BioNut) at Karolinska Institutet, has been awarded a grant of approximately 1.75 million US dollars for four years, from the National Institute of Health (NIH), USA.

World-Wide FINGERS (WW-FINGERS) is the first global network of clinical trials for risk reduction and prevention of dementia and Alzheimer's disease through multidomain interventions. The network convenes research teams from over 30 countries, and is led by Professor Miia Kivipelto from the Center for Alzheimer Research, Karolinska Institutet. The main scope, scientific strategy and activities of the WW-FINGERS network have been published today (July 6, 2020) in Alzheimer's & Dementia.

Researchers at Karolinska Institutet have imaged tau protein in the brains of living patients with Alzheimer’s disease. The amount and spread of tau proved a predictor of future memory loss. Brain imaging for measuring tau can be useful both for improving diagnosis and for developing more effective treatments, say the researchers. The study is published in the journal Molecular Psychiatry.

Märta Dahlström, PhD-student at the Division of Clinical Geriatrics. On April 30, 2020 you will defend your thesis: "Drug discovery targeting non-amyloid pathways in Alzheimer’s disease", what's the main focus of the thesis?

She receives the grant for ”New diagnostic tools and treatment for Alzheimer's disease, traumatic brain injury and small vascular disease” and it is distributed over three years.

Per Nilsson, at the Division of Neurogeriatrics, NVS, receives 1 000 000 SEK in grants from Torsten Söderberg's Foundation.

Meet your colleagues, while getting some activity and fresh air.
Wednesday: Akademiska Stråket 1, Bioclinicum, Solna
Friday: Blickagången 16, NEO, Flemingsberg
@ 12 am, the walk will be 30-40 minutes and at an easy pace.

New research from Stockholm University and Karolinska Institutet shows that viruses interact with proteins in the biological fluids of their host which results in a layer of proteins on the viral surface. This coat of proteins makes the virus more infectious and facilitates the formation of plaques characteristic of neurodegenerative diseases such as Alzheimer's disease. The study is published in Nature Communications.

Professor Miia Kivipelto and her team - the Nordic Brain Network - provided a major contribution to the development and definition of the guidelines, given the expertise and experience in the field of risk and protective factors for dementia and AD.